Skip to main content

Easai – Promising Alzheimer’s Drug?

I saw this in Alzheimer’s research news. I wondered if Eisai looks like a strong company. Robinhood gives it 50% hold, 25% buy, 25%sell. From the Field: Aducanumab Approved for Treatment of Alzheimer’s disease (AD) On June 2021, the US Food and Drug Administration (FDA) gave ‘accelerated approval’ for the anti-amyloid drug aducanumab, which is […]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.